Jacob S Witt1, Robert W Gao2, Lisa J Sudmeier3, Stephen A Rosenberg4, David M Francis1, Charles R Wallace1, Rupak K Das1, Bethany M Anderson5. 1. Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI. 2. Radiation Oncology, University of Minnesota Medical School, Minneapolis, MN. 3. Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA. 4. Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL. 5. Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI. Electronic address: anderson@humonc.wisc.edu.
Abstract
PURPOSE: Studies have shown that an additional mean dose of 1 Gy to the heart can increase the relative risk of cardiac events. The purpose of this study was to quantify the dose delivered to the heart and left anterior descending artery (LAD) in a series of patients with left-sided breast cancer (BC) or ductal carcinoma in situ treated with multicatheter-accelerated partial breast irradiation (MC-APBI) at a single institution. METHODS AND MATERIALS: Patients with left-sided BC or ductal carcinoma in situ treated consecutively from 2005 to 2011 with MC-APBI were retrospectively identified. Cardiac and LAD contours were generated for each patient. Cardiac dosimetry and distance to the planning target volume were recorded. Patient health records were reviewed and cardiac events were recorded based on Common Terminology Criteria for Adverse Events version 4.0. RESULTS: Twenty consecutive patients with left-sided BC treated with MC-APBI were retrospectively identified. Median followup was 41.4 months. Mean equivalent dose in 2 Gy fractions delivered to the heart and LAD were 1.3 (standard deviation: 0.7, range: 0.2-2.9) and 3.8 (standard deviation: 3.0, range: 0.4-11.3) Gy, respectively. There was an inverse linear relationship (R2 = 0.52) between heart-to-lumpectomy cavity distance and mean heart equivalent dose in 2 Gy fractions. One patient (5%) experienced symptomatic cardiac toxicity. CONCLUSIONS: MC-APBI consistently delivers average doses to the heart and LAD that are similar to those achieved in most series with deep inspiration breath-hold and lower than free-breathing radiotherapy techniques. Distance from the heart to the lumpectomy cavity and the availability of other heart-sparing technologies should be considered to minimize the risk of cardiac toxicity.
PURPOSE: Studies have shown that an additional mean dose of 1 Gy to the heart can increase the relative risk of cardiac events. The purpose of this study was to quantify the dose delivered to the heart and left anterior descending artery (LAD) in a series of patients with left-sided breast cancer (BC) or ductal carcinoma in situ treated with multicatheter-accelerated partial breast irradiation (MC-APBI) at a single institution. METHODS AND MATERIALS: Patients with left-sided BC or ductal carcinoma in situ treated consecutively from 2005 to 2011 with MC-APBI were retrospectively identified. Cardiac and LAD contours were generated for each patient. Cardiac dosimetry and distance to the planning target volume were recorded. Patient health records were reviewed and cardiac events were recorded based on Common Terminology Criteria for Adverse Events version 4.0. RESULTS: Twenty consecutive patients with left-sided BC treated with MC-APBI were retrospectively identified. Median followup was 41.4 months. Mean equivalent dose in 2 Gy fractions delivered to the heart and LAD were 1.3 (standard deviation: 0.7, range: 0.2-2.9) and 3.8 (standard deviation: 3.0, range: 0.4-11.3) Gy, respectively. There was an inverse linear relationship (R2 = 0.52) between heart-to-lumpectomy cavity distance and mean heart equivalent dose in 2 Gy fractions. One patient (5%) experienced symptomatic cardiac toxicity. CONCLUSIONS:MC-APBI consistently delivers average doses to the heart and LAD that are similar to those achieved in most series with deep inspiration breath-hold and lower than free-breathing radiotherapy techniques. Distance from the heart to the lumpectomy cavity and the availability of other heart-sparing technologies should be considered to minimize the risk of cardiac toxicity.
Authors: Mary Feng; Jean M Moran; Todd Koelling; Aamer Chughtai; June L Chan; Laura Freedman; James A Hayman; Reshma Jagsi; Shruti Jolly; Janice Larouere; Julie Soriano; Robin Marsh; Lori J Pierce Journal: Int J Radiat Oncol Biol Phys Date: 2010-04-24 Impact factor: 7.038
Authors: Todd Swanson; Inga S Grills; Hong Ye; Amy Entwistle; Melanie Teahan; Nicola Letts; Di Yan; Joana Duquette; Frank A Vicini Journal: Am J Clin Oncol Date: 2013-02 Impact factor: 2.339
Authors: Candace Correa; Eleanor E Harris; Maria Cristina Leonardi; Benjamin D Smith; Alphonse G Taghian; Alastair M Thompson; Julia White; Jay R Harris Journal: Pract Radiat Oncol Date: 2016-09-17
Authors: Sarah C Darby; Marianne Ewertz; Paul McGale; Anna M Bennet; Ulla Blom-Goldman; Dorthe Brønnum; Candace Correa; David Cutter; Giovanna Gagliardi; Bruna Gigante; Maj-Britt Jensen; Andrew Nisbet; Richard Peto; Kazem Rahimi; Carolyn Taylor; Per Hall Journal: N Engl J Med Date: 2013-03-14 Impact factor: 91.245
Authors: J Cuzick; H Stewart; L Rutqvist; J Houghton; R Edwards; C Redmond; R Peto; M Baum; B Fisher; H Host Journal: J Clin Oncol Date: 1994-03 Impact factor: 44.544
Authors: Jean M Moran; Merav A Ben-David; Robin B Marsh; James M Balter; Kent A Griffith; James A Hayman; Lori J Pierce Journal: Int J Radiat Oncol Biol Phys Date: 2009-06-18 Impact factor: 7.038